Formulary guidance and transparency from P&T to point of care


Reality Check on Narcolepsy

Market access for narcolepsy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, more than 66% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In March 2019, the FDA approved Jazz Pharmaceuticals plc's Sunosi (solriamfetol) to improve wakefulness in adults with excessive daytime sleepiness from narcolepsy or obstructive sleep apnea
  • Key Findings: Generics are preferred over brands, and contracting may be limited for Xyrem with no direct competition  

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.